Key result
Combining a triple biomarker test at admission with serial high-sensitivity troponin measurements is estimated to reduce direct hospital costs by €66 to €205 per patient with suspected NSTEMI.
Why the study?
Does a triple biomarker test at admission reduce direct hospital costs and improve discharge rates in suspected NSTEMI patients compared to serial HsTn measurements?
Population
Suspected non-ST elevation myocardial infarction (NSTEMI) patients
Comparison
Triple biomarker test at hospital admission vs Current serial HsTn measurement
Design
Other
Authors
Loading...
May reduce costs in suspected NSTEMI evaluation; leaves open confirmation in prospective trials before practice change.
Does a triple biomarker test at admission reduce direct hospital costs and improve discharge rates in suspected NSTEMI patients compared to serial HsTn measurements?
Effect estimate: €66 to €205 reduction
A triple biomarker test at admission combined with serial HsTn measurements may be a cost-effective strategy for suspected NSTEMI patients, reducing direct hospital costs by up to 11.3%.
Kip et al. (2016) studied suspected non-ST elevation myocardial infarction. Triple biomarker test (copeptin, heart-type fatty acid binding protein, and high-sensitivity troponin) combined with HsTn measurements after 2 and 6 hours vs. Current serial HsTn measurement (performed 0, 2, and 6 h after admission) was evaluated on Direct hospital costs per patient (€66 to €205 reduction). Combining a triple biomarker test at admission with serial high-sensitivity troponin measurements is estimated to reduce direct hospital costs by €66 to €205 per patient with suspected NSTEMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: